RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
FOà R
Collezione AO Cuneo
Items : 47
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML. in Cancer / Cancer. 2023 Sep 1;129(17):2637-2644. doi: 10.1002/cncr.34923. Epub 2023 Jun 24.
2023
AO Cuneo
AOU Novara
Pizzuti M; Crugnola M; Malato A; Fava C; Bocchia M; Vincelli I; Luzi D; Rapezzi D; Abruzzese E; Stagno F; Murgano P; Sancetta R; Leporace AP; Scortechini AR; Crisà E; Binotto G; Maggi A; Loglisci G; Mulas O; Bonifacio M; Sorà F; Annunziata M; Russo S; Crescenzi SL; Attolico I; Bucelli C; Cavazzini F; Miggiano MC; Capodanno I; et alii...
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. in American journal of hematology / Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Laurenti L; Molica S; Zatta I; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Rigolin GM; Sportoletti P; Trimarco V; Murru R; Marchetti M; Pietrasanta D; Cibien F; Vitale C; Sanna A; Derenzini E; Proietti G; Ferrarini I; Reda G; Mauro FR; Scarfò L; Gentile M; Farina L; et alii...
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):201-204. doi: 10.1002/hon.3047. Epub 2022 Aug 19.
2023
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Novara
Marasca R; Foà R; Ballotta L; Moia R; Cuneo A; Chiurazzi F; Reda G; Gottardi D; Orsucci L; Maccaferri M; De Paoli L;
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria
Laurenti L; Cuneo A; Foà R; Trentin L; Coscia M; Rigolin GM; Mattiello V; Gattei V; Sportoletti P; Scortechini I; Moia R; Gentile M; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Giordano A; Baratè C; Quaresmini G; Leone MMA; Farina L; Fresa A; Piciocchi A; Vitale C; Reda G; Visentin A; et alii...
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. in Blood advances / Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596.
2023
AO Cuneo
AOU Città della Salute di Torino
Vitale A; Trappolini S; Guarini A; Latte G; Di Bartolomeo P; Cassibba V; Candoni A; Bonifacio M; De Fabritiis P; Bocchia M; Fracchiolla N; Mattei D; Martinelli G; Mauro E; Zappasodi P; Borlenghi E; Marbello L; Audisio E; Scattolin AM; De Propris MS; Elia L; Messina M; Paoloni F; Spinelli O; Santoro A; Della Starza I; Bassan R; Chiaretti S; Fazi P; et alii...
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara
Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study. in Leukemia / Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.
2023
AO Cuneo
Gattei V; Del Poeta G; Foà R; Di Raimondo F; Tafuri A; Zaja F; Fronza G; Morabito F; Gentile M; Cuneo A; Del Principe MI; Postorino M; Laureana R; Olivieri J; Chiarenza A; Reda G; Laurenti L; Marasca R; Bulian P; Degan M; Polesel J; Tissino E; Pozzo F; Zucchetto A; Papotti R; Vit F; Bittolo T; Rossi FM; Bomben R; et alii...
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. in Blood advances / Blood Adv. 2022 Mar 22;6(6):1742-1753. doi: 10.1182/bloodadvances.2021004821.
2022
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
Baccarani M; Foà R; Fazi P; Vignetti M; Cavo M; Sartor C; Paolini S; Granier M; Wang M; Zhu Z; Abbenante MC; Galieni P; Fabbiano F; Trappolini S; Tosi P; Bonifacio M; Martelli MP; D'Ardia S; Cuneo A; Tedeschi A; Frison L; Bocchia M; Vitale A; Candoni A; Selleri C; Simonetti F; Lunghi M; de Fabritiis P; Lemoli RM; et alii...
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. in American journal of hematology / Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Alessandria
Cuneo A; Trentin L; Foà R; Molica S; Laurenti L; Pravato S; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Coscia M; Piazza F; Reda G; Fresa A; Ciolli S; Scarfò L; Sportoletti P; Pietrasanta D; Vitale C; Mauro FR; Cibien F; Visentin A;
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. in Haematologica / Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara
Cuneo A; Laurenti L; Ghia P; Foà R; Trentin L; Pompili M; Tedeschi A; Mauro FR; Del Poeta G; Scarfò L; Autore F; Tomasso A; Di Sevo D; Arena V; Deodato M; Ielo C; Frustaci AM; Piciocchi A; Rughini A; Cassin R; Albano F; Quaglia FM; Pennese E; Moia R; Gentile M; Murru R; Motta M; Coscia M; Visentin A; et alii...
Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review. in Journal of the European Academy of Dermatology and Venereology : JEADV / J Eur Acad Dermatol Venereol. 2022 Jul;36(7):1003-1015. doi: 10.1111/jdv.18074. Epub 2022 Mar 29.
2022
AO Cuneo
ASL Cuneo 1
AOU Alessandria
Botti S; Foà R; Olivieri A; De Cecco V; Samarani E; Cioce M; Cannici C; Mordini N; Rostagno E; Campanati A;
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. in British journal of haematology / Br J Haematol. 2022 Feb;196(3):559-565. doi: 10.1111/bjh.17890. Epub 2021 Oct 11.
2022
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Novara
Saglio G; Breccia M; Abruzzese E; Accurso V; Attolico I; Barulli S; Bergamaschi M; Binotto G; Foà R; Sportoletti P; Stagno F; Tafuri A; Tiribelli M; Rita Scortechini A; Sorà F; Sancetta R; Russo S; Rosti G; Rege-Cambrin G; Pregno P; Rapezzi D; Pizzuti M; Cristina Miggiano M; La Barba G; Latagliata R; Leonetti Crescenzi S; Levato L; Loglisci G; Lucchesi A; et alii...
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. in Journal of hematology & oncology / J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.
2022
AO Cuneo
ASL Vercelli
ASL Cuneo 1
AOU Alessandria
Ghia P; Stamatopoulos K; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Wróbel T; Segundo LYS; Visentin A; Vitale C; Vukovic V; Wasik-Szczepanek E; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; Varettoni M; Shrestha A; Šimkovi? M; Smirnova S; Špa?ek M; Sportoletti P; Stanca O; Stavroyianni N; Te Raa D; et alii...
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. in Haematologica / Haematologica. 2022 Apr 1;107(4):868-876. doi: 10.3324/haematol.2021.278304.
2022
AO Cuneo
Visentin A; Bonaldi L; Rigolin GM; Mauro FR; Martines A; Frezzato F; Pravato S; Gargarella LR; Bardi MA; Cavallari M; Volta E; Cavazzini F; Nanni M; Facco M; Piazza F; Guarini A; Foà R; Semenzato G; Cuneo A; Trentin L;
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. in Haematologica / Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851.
2022
AO Cuneo
AOU Città della Salute di Torino
Foà R; Ferrara F; Chiaretti S; Defina M; Pizzolo G; Castella B; Rizzari C; Del Principe MI; Giglio F; Giaccone L; Fracchiolla NS; Chiusolo P; Zappasodi P; La Starza R; Favre C; Tanasi I; Gurrieri C; Cerrano M; Forghieri F; Malagola M; Dargenio M; Scattolin AM; Papayannidis C; Curti A; Olivi M; Bonifacio M;
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. in Frontiers in oncology / Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.
2022
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
Laurenti L; Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Reda G; Scarfò L; Angotzi F; Cellini A; Pravato S; Molica S; Marchetti M; Murru R; Gozzetti A; Gentile M; Rigolin GM; Quaglia FM; Sanna A; Sportoletti P; Cibien F; Mattiello V; Mauro FR; Catania G; Fresa A; Vitale C; Visentin A;
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara
Foà R; Chiarenza A; Penna G; Gottardi D; Derenzini E; Levato L; Orsucci L; Gattei V; Gentile M; Sanna A; Gozzetti A; Olivieri J; Murru R; Baratè C; Leone M; Stefoni V; Malerba L; Ibatici A; Tisi MC; Marasca R; Chiurazzi F; Varettoni M; Farina L; Del Poeta G; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; et alii...
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. in Cancers / Cancers (Basel). 2021 Jun 29;13(13):3240. doi: 10.3390/cancers13133240.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Trentin L; Gentile G; Girmenia C; Martelli M; Gaidano G; Foà R; Cuneo A; Tedeschi A; Molica S; Coscia M; Noto A; Guarente V; Stelitano C; Del Poeta G; Giordano A; Rigolin GM; De Paoli L; Murru R; Gentile M; Levato L; Ielo C; Laurenti L; Ciolli S; Vitale C; Frustaci AM; Chiarenza A; Sportoletti P; Reda G; Visentin A; et alii...
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. in Blood / Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Griggio V; Vitale C; Coscia M; Salvetti C; Gaidano G; Mauro FR; Foà R; Boccadoro M; Scarfò L; Cuneo A; Tedeschi A; Reda G; Orsucci L; Trentin L; De Paoli L; Montalbano MC; Boccellato E; Perutelli F; Marchetti M; Pennese E; Gentile M; Rivela P; Murru R; Laurenti L; Rigolin GM; Vassallo F; Cassin R; Porrazzo M; Schiattone L; et alii...
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. in Haematologica / Haematologica. 2021 Jun 1;106(6):1559-1568. doi: 10.3324/haematol.2020.247973.
2021
AOU Città della Salute di Torino
AO Cuneo
Vitale A; Cattaneo C; Mattei D; Fracchiolla N; Cerrano M; Cairoli R; Candoni A; Papayannidis C; De Fabritiis P; Di Raimondo F; Capria S; Apicella V; Spinelli O; Santoro A; Pierini V; Puzzolo MC; Lauretti A; Canichella M; La Starza R; Albertini Petroni G; Elia L; Ansuinelli M; Taherinasab A; Cavalli M; Cafforio L; Piciocchi A; Della Starza I; Messina M; Chiaretti S; et alii...
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. in Leukemia / Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Sportoletti P; Laurenti L; Gattei V; Gaidano G; Polliack A; Foà R; Rossi D; Cuneo A; Di Raimondo F; Rigolin GM; Bomben R; Biagi A; Del Giudice I; Angeletti I; Rago A; Arrigo G; Vigna E; Botta C; Tripepi G; Fraticelli V; Zucchetto A; Scortechini I; Loseto G; Consoli U; Rossi FM; Pietrasanta D; Murru R; Chiarenza A; Condoluci A; et alii...
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara
Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. in Blood / Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.
2021
AO Cuneo
AOU Alessandria
Guarini A; Mauro FR; Cuneo A; Vignetti M; Peragine N; Mariglia P; Nanni M; Marchetti M; Trentin L; Molica S; Sportoletti P; Reda G; Albano F; Arena V; Piciocchi A; Cafforio L; Ilari C; Raponi S; Cura F; García-Jacobo RE; Foà R; Melandri A; Bardi A; Del Giudice I; Rigolin GM;
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. in Leukemia / Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Ghia P; Stamatopoulos K; Montserrat E; Cuneo A; Foà R; Rambaldi A; Coscia M; Yassin M; Vitale C; van Kampen R; San Segundo LY; Wróbel T; Wasik-Szczepanek E; Varettoni M; Visentin A; Trentin L; Van Der Spek E; van Gelder M; Te Raa D; Tonino SH; Tadmor T; Stavroyianni N; Stanca O; Sportoletti P; Šimkovi? M; Špa?ek M; Shrestha A; Saghumyan G; Reda G; et alii...
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26.
2021
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Cuneo A; Foà R; Marchetti M; Gentile M; Vignetti M; Mauro FR; Crea E; Marasca R; Laurenti L; Molinari AL; Pietrasanta D; Quaglia FM; Sportoletti P; Paolini R; Varettoni M; Gaidano G; Murru R; Vitagliano O; Coscia M; Farina L; Cibien F; Zamprogna G; Arena V; Visentin A; Reda G; Cavazzini F; Piciocchi A; Montillo M; Rigolin GM; et alii...
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. in Frontiers in oncology / Front Oncol. 2021 Apr 15;11:637186. doi: 10.3389/fonc.2021.637186. eCollection 2021.
2021
AO Cuneo
Puzzolo MC; Del Giudice I; Peragine N; Mariglia P; De Propris MS; Cappelli LV; Trentin L; Reda G; Cuneo A; Molica S; Piciocchi A; Arena V; Mauro FR; Guarini A; Foà R;
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.
2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria
AOU Novara
Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. in Leukemia / Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
2020
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara
Foà R; Rambaldi A; Montserrat E; Rossi G; Stamatopoulos K; Coscia M; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Shah N; Shrestha A; Stanca O; Ortiz Pareja M; Papaioannou M; Rossi D; Kalashnikova O; Hakobyan Y; Doubek M; Enrico A; Dimou M; Andres M; Chiarenza A; Nikitin E; Dos Santos G; Barna G; Yassin M; Pocali B; Sportoletti P; et alii...
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.
2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria
Foà R; Guarini AR; Raponi S; De Propris MS; Della Starza I; Del Giudice I; Albano F; Cuneo A; Neri A; Piciocchi A; Vignetti M; Nanni M; Musolino C; Battistini R; Del Poeta G; Pietrasanta D; Gozzetti A; Liberati AM; Reda G; Tedeschi A; Re F; Soddu S; Mauro FR; Angelucci E; Zaja F; Coscia M; Ilariucci F; Molica S;
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara
Vignetti M; Foà R; Ghia P; Cimino G; Cavallari M; Cucci R; de la Serna J; Ferrarini I; Medina Perez A; Mauro FR; Coscia M; Di Raimondo F; Farina L; Molica S; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Schuster SJ; Shah NN; Sehgal AR; Pu JJ; et alii...
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. in Leukemia / Leukemia. 2020 Aug;34(8):2260-2261. doi: 10.1038/s41375-020-0904-z. Epub 2020 Jun 18.
2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AO Cuneo
Pregno P; Rege-Cambrin G; Rosti G; Stagno F; Tiribelli M; Foà R; Saglio G; Luciano L; Iurlo A; Latagliata R; Gugliotta G; Galimberti S; Gozzini A; Fava C; Bonifacio M; Castagnetti F; Bocchia M; Abruzzese E; Breccia M;
HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.
2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli
AOU Novara
Boccadoro M; Gattei V; Foà R; Massaia M; Gaidano G; Zenz T; Bernardi R; Mauro FR; Laurenti L; Del Poeta G; Kodipad AA; Omedè P; Magliulo D; Rossi D; Marchetti M; Bonello L; Pozzato G; Bo MD; Kopecka J; Bomben R; Salvetti C; Riganti C; Todaro M; Vitale C; Griggio V; Coscia M;
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. in Blood / Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.
2019
AO Cuneo
Amadori S; Arcese W; Lo-Coco F; Voso MT; Lavorgna S; Ottone T; Irno-Consalvo M; Del Principe MI; Buccisano F; Vignetti M; Maurillo L; Fazi P; La Sala E; Alati C; Fracchiolla NS; Capelli D; Foà R; Tieghi A; Chierichini A; Fabbiano F; Tafuri A; Cuneo A; Albano F; Mazza P; Martelli MP; Luppi M; Martinelli G; Lanza F; Storti G; et alii...
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. in Hematological oncology / Hematol Oncol. 2019 Oct;37(4):508-512. doi: 10.1002/hon.2655. Epub 2019 Aug 5.
2019
AOU Città della Salute di Torino
AO Cuneo
Semenzato G; Trentin L; Foà R; Cuneo A; Coscia M; Cassin R; Laurenti L; Tedeschi A; Cesini L; Piazza F; Rigolin GM; Molica S; Vitale C; Reda G; Autore F; Mauro FR; Deodato M; Visentin A;
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. in British journal of haematology / Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31.
2019
AOU Città della Salute di Torino
AO Cuneo
Laurenti L; Foà R; Cuneo A; Scarfò L; Tedeschi A; Efremov DG; D'Arena G; Gentile M; Levato L; Murru R; Sportoletti P; Coscia M; Ciolli S; Ibatici A; Reda G; Rigolin GM; Del Poeta G; Trentin L; Schiattone L; Mauro FR; Frustaci A; Piciocchi A; Autore F; Morelli F; Innocenti I;
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. in Cancers / Cancers (Basel). 2019 Jun 26;11(7):896. doi: 10.3390/cancers11070896.
2019
AOU Città della Salute di Torino
AO Cuneo
Laurenti L; Ferrajoli A; Foà R; Sica S; Visentin A; Reda G; Tisi MC; Vitale C; Rigolin GM; Ferretti A; Efremov DG; Vincelli D; Murru R; D'Arena G; Falcucci P; Molica S; Morabito F; Gentile M; Frustaci AM; Mauro FR; Gozzetti A; Cuneo A; Visco C; Coscia M; Cortelezzi A; Trentin L; Corrente F; Innocenti I; Strati P; et alii...
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation / Biol Blood Marrow Transplant. 2019 Dec;25(12):2388-2397. doi: 10.1016/j.bbmt.2019.07.037. Epub 2019
2019
AO Cuneo
AOU Città della Salute di Torino
ASL Torino 4
Bonifazi F; Mammoliti S; Oldani E; Leotta S; Cortelezzi A; Risitano AM; Orciuolo E; Vacca A; Sorasio R; Dominietto A; Tecchio C; Olivieri A; Carella AM; Malagola M; Albano F; Zallio F; Mancini S; Irrera G; Santarone S; Colombo AA; Tringali S; Iori AP; Diral E; Zucchetti E; Perruccio K; Sica S; Picardi A; Busca A; Giglio F; et alii...
Myelodysplastic syndromes with hypocellular marrow: Clinical characteristics and evaluation of outcome in HemaSphere
2018
ASL Biella
ASL Città di Torino
ASL Asti
ASL Torino 4
ASL Torino 5
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Alessandria
ASL Novara
Santini V; Gioia D; Masiera E; Poloni A; Ferrero D; Fragasso A; Finelli C; Salvi F; Gaidano G; Oliva EN; Catarini M; Cametti G; Bonferroni M; Danise P; Tassara R; Allione B; Cilloni D; Castelli A; Centurioni R; Ciravegna G; Visani G; Musto P; Balleari E; Biale L; Capelli D; Frairia C; Galimberti S; Giaccone L; Macchi S; et alii...
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. in Haematologica / Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8.
2017
AO Ordine Mauriziano
AOU Città della Salute di Torino
AO Cuneo
Piciocchi A; Boncompagni R; Orlando S; Cuneo A; Galieni P; Marasca R; Vannata B; Pozzato G; Efremov DG; Molica S; Coscia M; Massaia M; D'Arena G; Del Poeta G; Mannina D; Mauro FR; Ciolli S; Autore F; Innocenti I; Laurenti L; Vincelli D; Liberati AM; Russo F; Foá R;
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. in Leukemia / Leukemia. 2015 Jun;29(6):1360-5. doi: 10.1038/leu.2015.21. Epub 2015 Feb 4.
2015
AO Cuneo
Riminucci M; Nicolai E; Trastulli F; Campanelli M; Autore F; Laurenti L; Rossi D; Sacchetti GM; Bellò M; Coscia M; Morabito F; Gentile M; Rago A; Cimino G; Biggi A; Paoloni F; Chauvie S; Mauro FR; Gaidano G; Guarini A; Gallamini A; Foà R;
2009
AO Cuneo
Giaccone L; Festuccia M; Sorasio R; Mordini N; Carnevale Schianca F; Patriarca F; Casini M; Paola Iori A; Foà R; Boccadoro M; Bruno B;
[Pleural effusion in a case of non-Hodgkin's lymphoma: diagnostic use of molecular analysis]. in Recenti progressi in medicina / Recenti Prog Med. 1990 Sep;81(9):568-70.
1990
AO Cuneo
Bonferroni M; Cavallero GB; di Celle PF; Gallamini A; Foà R;